Dolby Laboratories (NYSE:DLB) Issues Quarterly Earnings Results

Dolby Laboratories (NYSE:DLB - Get Free Report) posted its earnings results on Wednesday. The electronics maker reported $0.84 EPS for the quarter, missing analysts' consensus estimates of $1.07 by ($0.23), Zacks reports. Dolby Laboratories had a return on equity of 11.19% and a net margin of 20.56%. Dolby Laboratories updated its FY 2025 guidance to 3.990-4.140 EPS and its Q2 2025 guidance to 1.190-1.340 EPS.

Dolby Laboratories Stock Down 0.0 %

NYSE DLB traded down $0.02 during trading hours on Wednesday, reaching $80.59. The company's stock had a trading volume of 405,447 shares, compared to its average volume of 450,844. Dolby Laboratories has a 1 year low of $66.35 and a 1 year high of $85.30. The firm's 50-day moving average price is $79.18 and its 200-day moving average price is $75.62. The company has a market capitalization of $7.69 billion, a price-to-earnings ratio of 29.74 and a beta of 0.98.

Dolby Laboratories Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, December 10th. Stockholders of record on Tuesday, December 3rd were given a dividend of $0.33 per share. This is an increase from Dolby Laboratories's previous quarterly dividend of $0.30. The ex-dividend date was Tuesday, December 3rd. This represents a $1.32 dividend on an annualized basis and a dividend yield of 1.64%. Dolby Laboratories's payout ratio is presently 48.71%.

Analysts Set New Price Targets

Several equities research analysts recently commented on DLB shares. Barrington Research reiterated an "outperform" rating and issued a $100.00 price objective on shares of Dolby Laboratories in a report on Monday. StockNews.com upgraded shares of Dolby Laboratories from a "buy" rating to a "strong-buy" rating in a research note on Wednesday, December 4th. Finally, Rosenblatt Securities restated a "buy" rating and set a $100.00 price objective on shares of Dolby Laboratories in a research report on Thursday, January 23rd.

Insider Activity

In other Dolby Laboratories news, SVP John D. Couling sold 50,000 shares of the business's stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $80.04, for a total value of $4,002,000.00. Following the sale, the senior vice president now owns 106,806 shares in the company, valued at $8,548,752.24. The trade was a 31.89 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Mark Andrew Sherman sold 12,338 shares of the firm's stock in a transaction dated Tuesday, December 17th. The shares were sold at an average price of $78.08, for a total value of $963,351.04. Following the transaction, the executive vice president now owns 62,397 shares of the company's stock, valued at approximately $4,871,957.76. The trade was a 16.51 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 135,917 shares of company stock worth $10,877,739 over the last quarter. Insiders own 38.39% of the company's stock.

Dolby Laboratories Company Profile

Dolby Laboratories, Inc creates audio and imaging technologies that transform entertainment at the cinema, DTV transmissions and devices, mobile devices, OTT video and music services, home entertainment devices, and automobiles. The company develops and licenses its audio technologies, such as AAC & HE-AAC, a digital audio codec solution used for a range of media applications; AVC, a digital video codec with high bandwidth efficiency used in various media devices; Dolby AC-4, a digital audio coding technology that delivers new audio experiences to a range of playback devices; and Dolby Atmos technology for cinema and various media devices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.